|Specificity:||The antibody MEM-154 reacts with an epitope on CD16 antigen that is residing in proximity to FG loop (probably BC or C'E loop). CD16 is a low affinity receptor for aggregated IgG (FcgammaRIII antigen). The antibody MEM-154 reacts with CD16+ granulocytes.
HLDA V; WS Code M MA068
HLDA V; WS Code NK NK51
Recommended dilution: 5-10 μg/ml
Positive control: PBL (peripheral blood lymphocytes)
Application note: The antibody MEM-154 does not react with CD16a present on NK cells in many subjects.
Application note: Non-reducing conditions.
The antibody MEM-154 blocks binding of human IgG to FcgammaRIII.
|Purity:||> 95% (by SDS-PAGE)|
|Purification:||Purified by protein-A affinity chromatography|
|Storage Buffer:||Azide free phosphate buffered saline (PBS), approx. pH 7.4; 0.2 μm filter sterilized.|
|Storage / Stability:||Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.|
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD16 (FcgammaRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcgammaRIII is expressed in two forms – FcgammaRIII-A and -B. FcgammaRIII-A is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcepsilonRI-gamma subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcgammaRIII-A is associated, moreover, with FcepsilonRI-beta subunit. Besides IgG, FcgammaRIII-A can be triggered also by oligomeric IgE. FcgammaRIII-B is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.|
*Gessner JE, Grussenmeyer T, Kolanus W, Schmidt RE: The human low affinity immunoglobulin G Fc receptor III-A and III-B genes. Molecular characterization of the promoter regions. J Biol Chem. 1995 Jan 20;270(3):1350-61.
*Kocher M, Siegel ME, Edberg JC, Kimberly RP: Cross-linking of Fc gamma receptor IIa and Fc gamma receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol. 1997 Oct 15;159(8):3940-8.
*Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T: IgE-mediated activation of NK cells through Fc gamma RIII. J Immunol. 2003 Mar 15;170(6):3054-8.
*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
*de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D, von dem Borne AE: A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol. 1996 Apr 15;156(8):3948-55.
*Tamm A, Schmidt RE: The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J Immunol. 1996 Aug 15;157(4):1576-81.
*Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997 Aug 1;90(3):1109-14.
*Gasdaska JR, Sherwood S, Regan JT, Dickey LF: An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol. 2012 Mar;50(3):134-41
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic